What we're reading, September 16, 2016: Donald Trump mentions using Medicaid to expand coverage and making birth control available without a prescription; medical marijuana could curb the opioid epidemic; and how rare diseases are becoming more common.
In contradiction to what his party has proposed in the past, Republican presidential nominee Donald Trump said he would use Medicaid to expand insurance coverage for poor people. According to Bloomberg, Trump made these comments during a filming for The Dr. Oz Show, but a spokesman said the candidate is not proposing an expansion of Medicaid. Trump further said he wants birth control to be available without a prescription. However, he also announced a new “pro-life coalition” with the president of a top national group opposing abortion to head the coalition, USA Today reported. Additionally, Trump said he would make the Hyde Amendment, which withholds some federal funds from being used for abortion, a permanent law.
The opioid epidemic in the United States has become an issue of national focus, but there may be an overlooked way to combat this problem. A study found that medical marijuana may be used to curb the growing opioid epidemic, reported The Washington Post. In states where medical marijuana has been made legal, there are fewer people using opioids, researchers concluded. As a result, there are fewer painkiller overdose deaths in those states.
Rare diseases are becoming more common, which may necessitate revisiting orphan drug incentives, writes Peter Ubel, MD, for Forbes. The government passed the Orphan Drug Act in 1983 in order to incentivize companies to create treatments for rare diseases, and the industry has become quite profitable with the rate of orphan drug approvals accelerating. Precision medicine has made rare diseases more common as people with a common illness, like cancer, may be diagnosed with a subcategory. With medical care becoming more precise, orphan drug incentives need to better align with clinical practices.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More